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Background. Urinary bladder sarcomatoid carcinoma (carcinosarcoma) is rare. The objective of this study was to examine the
epidemiology,naturalhistory,andprognosticfactorsofurinarybladdercarcinosarcomausingpopulation-basedregistry.Methods.
The Surveillance, Epidemiology, and End Results (SEER) Program database was used to identify cases by tumor site and histology
codes. The association between clinical and demographic characteristics and long-term survival was examined. Results.At o t a l
of 221 histology conﬁrmed cases were identiﬁed between 1973 and 2004, this accounted for approximately 0.11% of all primary
bladder tumors during the study period. Median age of the patients was 75 years (range 41–96). Of the patients with a known
tumor stage (N = 204), 72.5% had a regional or distant stage; 98.4% of patients with known histology grade (N = 127), had
poorly or undiﬀerentiated histology. Multiple primary tumors were indentiﬁed in about 40% of study subjects. The majority of
patients (95.9%) received cancer directed surgery, 35.8% had radical or partial cystectomy, 15.8% of patients received radiation
therapy combination with surgery. The median overall survival was 14 months (95% CI 7–21 months). 1-, 5-, and 10-year cancer
speciﬁc survival rate were 53.9%, 28.4% and 25.8%. In a multivariate analysis, only tumor stage was found to be a signiﬁcant
prognostic factor for disease-speciﬁc survival. Conclusions. Urinary bladder carcinosarcoma commonly presented as high grade,
advanced stage and aggressive behavior with a poor prognosis. Emphasis on early detection, including identiﬁcation of risk factors
is needed to improve the outcome for patients with this malignancy.
1.Introduction
Sarcomatoid carcinoma (Carcinosarcomas) is deﬁned by the
World Health Organization as a biphasic tumor consisting
of malignant epithelial and mesenchymal elements [1].
Carcinosarcoma of the urinary bladder is a rare neoplasm.
Approximately 70 cases have been reported in the literature,
mostoftenasasinglecasereportorlimitedseries[2–10]with
focus on histopathological characteristics. Microscopically,
carcinosarcomas are biphasic tumors made of an intimate
admixture of carcinomatous and sarcomatous components
with abrupt or gradual transition from one to the other.
In most cases, the epithelial component consists of high-
grade transitional cell carcinoma with possible epidermoid
and/or glandular diﬀerentiation, while the heterologous
component consists of chondrosarcoma, malignant ﬁbrous
histiocytoma, osteosarcoma, leiomyosarcoma, ﬁbrosarcoma,
or rhabdomyosarcoma [7–10]. Clinically, carcinosarcomas
occur more commonly in older males, and present as
advanced stage, rapidly growing polypoid neoplasms [1–6].
The histogenesis of carcinosarcomas remains a matter of
controversy [11–17]. Some investigators suggested that these
tumors develop as a result of undiﬀerentiated, totipotential
neoplastic cells that undergo multiple pathways of terminal
diﬀerentiation into either mesenchymal or epithelial ele-
ments. This theory is supported by the presence of epithelial
markers(cytokeratinorEMA)inmesenchymalareasandthe2 Sarcoma
presence of ultrastructural features (desmosomes or tonoﬁl-
aments) of epithelial diﬀerentiation in sarcomatoid elements
[11]. Others believe that in cases where diﬀerent compo-
nents share no common features on immunohistochemical
and electron microscopic examinations, carcinosarcomas
might be the result of true “collision” tumors, where both
malignant epithelial and mesenchymal components arise
independently from each other [15]. Several investigators
evaluated clonality in both malignant epithelial and mes-
enchymal elements using genetics or molecular techniques.
The tumor cells from both tumor components showed
monoclonality and clonal identity in all cases studied,
suggesting a monoclonal origin [12, 13, 16].
In contrast to well-described histopathological ﬁndings,
the demographic features and clinical behavior of these
tumors remain ill-deﬁned in this disease, and the issues
of the prognosis, treatment of those tumors have rarely
been speciﬁcally addressed. In this population-based study,
a comprehensive analysis of patients with carcinosarcoma of
the urinary bladder identiﬁed in the SEER Program database
was performed.
2. Methods
2.1. Data Source. Surveillance, Epidemiology, and End
Results (SEER) databases included patient records from
multiple sites across the United States. The database was
designed to reﬂect overall characteristics of the United
States, including the variety of racial/ethnic groups, and
geographical locations. SEER 9, 13, and 17 registries cover
approximately 9.5%, 13.8%, and 26.2% of the total U.S.
population, respectively [18]. Data for this study were
obtained from SEER∗Stat public-use data ﬁles, available on
the internet at the National Cancer Institute web site.
2.2. Study Population. The cases of carcinosarcoma were
extracted from the SEER on the basis of anatomic site (ICD-
O-2 codes C67.0–C67.9) and histologic type (ICD-O code
8980 and 8981) for those patients ﬁrst diagnosed and/or
treated between January 1973 and December 2004. 198,317
adult patients with bladder neoplasms were identiﬁed in the
SEER 17 registries, including 221 patients with carcinosar-
coma of the urinary bladder.
The SEER system collects data regarding extent of disease
at diagnosis, and classiﬁes patients as having local, regional
(extension into adjacent tissues or nodal involvement), or
distant disease. It incorporates the World Health Organi-
zation’s standard grading system used with four separate
categories (well, moderately well, poorly diﬀerentiated, and
undiﬀerentiated) [18].
2.3. Statistical Analysis. SEER∗Stat 6.2.4 (Surveillance
Research Program, National Cancer Institute) was used
for incidence analysis [18]. Age-adjusted incidence rates
and their 95% CIs were calculated for carcinosarcoma of
the urinary bladder for all patients, for men and women
separately, and for each of the 3 broad categories of race
Table 1: Age adjusted incidence rate of sarcomatoid carcinoma
(carcinosarcoma) of the urinary bladder per 100,000 populations.
Age-adjusted incidence rate∗95% CI
Overall 0.02 0.02-0.03
Gender
Male 0.03 0.03-0.04
Female 0.01 0.01-0.02
Race
White 0.02 0.02-0.03
Black 0.02 0.01–0.04
Others 0.01 0.00–0.03
∗Rates are per 100,000 population (95% conﬁdence interval) age-adjusted
to year 2000 U.S. Standard population.
(whites, blacks, and other). For calculation of the age-
adjusted incidence rates, the US general population for the
year 2000 was used as a standard population.
Discrete data are reported as frequencies and compared
by chi-square and Fisher’s exact tests as appropriate. Con-
tinuous data are reported as mean ± S Da n dc o m p a r e db y
student’s t-test. Cases identiﬁed at the time of autopsy or
by death certiﬁcate only or with more than one primary
were excluded from survival analyses. Survival duration was
measured by the Kaplan-Meier method [19]a n dc o m p a r e d
by the log rank test. The statistical independence between
prognostic variables was evaluated by multivariate analysis
by the Cox proportional hazard model [20]. All other
statistical calculations were performed by SPSS 12.0 (Apache
Software Foundation 2000). Comparative diﬀerences were
consideredstatisticallysigniﬁcantwhenthe P valuewas<.05.
3. Results
3.1. Frequency and Incidence. Between 1973 and 2004, a total
of 198,317 patients with bladder neoplasms were identiﬁed
in the SEER 17 registries, including 221 (0.11%) patients
with histologically conﬁrmed carcinosarcoma of the urinary
bladder.
Usinglinkedpopulationﬁles,theincidenceofcarcinosar-
coma of the urinary bladder was calculated as a rate per
100,000 per year, age adjusted to year 2000 U.S. standard
population. An age-adjusted incidence of 0.02 per 100,000
was observed (2 per 10,000,000 persons per year). Detailed
incidence data by gender and race are included in Table 1.
3.2. Patient and Tumor Characteristics. The median age at
diagnosis was 75 years, with a range of 41 to 96 years. The
male to female ratio was 1.9:1. The majority of patients
(89.1%) were white, while African American accounted
for 6.8%. Other ethnicities accounted for 4.1%. Details
of patient and tumor characteristics of study cohort are
included in Table 2.
The most common location of carcinosarcomas was the
lateral wall of the bladder, with the dome, trigon, anterior,
and posterior walls being less common. Of the 127 patients
whose histology grade was available, 125 (98.4%) had poorlySarcoma 3
Table 2: Characteristics of 221 patients with sarcomatoid carci-
noma (carcinosarcoma) of the urinary bladder diagnosed between
January 1973 and December 2004.
Characteristics N (%)
Age Mean ± SD 75 ± 11
Gender
Male 144 (65.2)
Female 77 (34.8)
Race
Black 15 (6.8)
White 197 (89.1)
Other 9 (4.1)
Married
Yes 128 (58)
No 90 (40.7)
Unknown 3 (1.3)
Location
Trigone of bladder 12 (5.4)
Dome of bladder 17 (7.7)
Lateral wall of bladder 35 (15.8)
Anterior wall of bladder 8 (3.6)
Posterior wall of bladder 20 (9.0)
Bladder neck 7 (3.2)
Ureteric oriﬁce 7 (3.2)
Overlapping lesion of bladder 42 (19.0)
Unknown 73 (33.0)
Grade
Moderately diﬀerentiated 2 (0.9)
Poorly diﬀerentiated 61 (27.6)
Undiﬀerentiated 64 (28.95)
Unknown 94 (42.5)
SEER stage
Localized 56 (25.3)
Regional 114 (51.6)
Distant 34 (15.4)
Unknown 17 (7.7)
Year of diagnosis
1973–1984 18 (8.1)
1985–1994 65 (29.4)
1995–2004 138 (62.5)
Cancer directed Surgery
Cystectomy 79 (35.8)
TURP 119 (53.8)
Unspeciﬁc surgery 14 (6.3)
None 9 (4.1)
Radiation
Before and after surgery 1 (0.5)
After surgery 34 (15.3)
Radiation only 2 (1.0)
Unknown 3 (1.3)
None 181(81.9)
SEER = Surveillance, Epidemiology, and End Results program TURBT =
transurethral resection for bladder tumor.
or undiﬀerentiated histology. Of 204 patients with known
SEER stage, 56 (27.5%) patients had localized stage; 114
(55.9%)hadregionalstage;and34(16.7%)haddistantstage.
A relatively large percentage (39.8%) of patients had two or
more primary tumors.
3.3. Treatment. Most of patients (95.9%) were treated with
cancer directed surgery (CDS), 35 (15.8%) of patients
received radiation therapy combined with cancer-directed
surgery. One patient received radiation before and after
surgery; 34 patients received radiation after surgery. Among
the patients who received cancer directed surgery, 119
(53.9%) patients underwent transurethral resection for
bladder tumor only and 79 (35.7%) patients underwent
partial or radical cystectomy. In 3.2% of cases, no surgical
or radiation therapy was given after the diagnosis was
established (Table 2).
3.4. Survival. The median duration of followup of the entire
cohort was 9 months (range 0–227 months); the median
duration of followup for censored patients was 162 months.
182 of 221 (82.4%) patients died during the followup period.
For bladder cancer speciﬁc survival analyses, the cases
that were identiﬁed at autopsy or on the basis of death
certiﬁcates only as well as those patients with more than
one primary tumor were excluded. A total of 132 patients
were included in bladder cancer speciﬁc survival analysis.
The median cancer speciﬁc survival was 14 months (95% CI
7–21 months) (Figure 1(a)).
Table 3 presents the 1-, 5-, and 10-year cancer-speciﬁc
survival rate according to patients and tumor characteristics.
There were signiﬁcant diﬀerences of cancer-speciﬁc survival
among SEER tumor stage groups (Figure 1(b)). However, no
signiﬁcant diﬀerence of cancer-speciﬁc survival was seen for
those who underwent cystectomy or transurethral resection
of bladder tumor (Figure 1(c)).
In a multivariate survival analyses by Cox proportional
hazard modeling, only tumor stage was identiﬁed as an
independent factor associated with cancer-speciﬁc survival.
Compared to patients with localized disease, patients with
regional and distant disease had a 2.2-and 8.9-fold increased
risk of dying from bladder cancer, respectively (Table 4).
4. Discussion
Because of the rarity of carcinosarcoma of the urinary blad-
der,previouslypublishedinformationhasbeenbasedoncase
series and anecdotal experiences. The clinical signiﬁcance
and biologic behavior of this subtype of primary bladder
cancer needs to be further characterized by performing more
extensive studies with long-term followup. This study, took
the advantage of the vast amount of data collected by the
SEER Program to examine the largest series of carcinosar-
coma of the urinary bladder reported to date, and represents
the ﬁrst population-based study of carcinosarcoma of the
urinary bladder in published literature.4 Sarcoma
Table 3:Median,1-,5-,and10-yearcancerspeciﬁcsurvivalofpatientswithsarcomatoidcarcinoma(carcinosarcoma)oftheurinarybladder
according to demographic and clinical characteristics.
Characteristics Median survival P-value Survival rate (%)
Months (95%
CI)
1-Year 5-Year 10-Year
All 14 (7, 21) 53.9 28.4 25.8
Tumor stage
Localized 21 (11, 31) <.001 67.8 34.8 29.0
Regional 10 (7, 13) 43.2 14.1 7.0
Distant 2 (1, 3) 8.7 4.4 n/a
Unstaged 6 (3, 9) 44.4 11.1 11.1
CDS
a
No surgery 4 (0, 10) 0.36 33.3 16.7 n/a
TURBT
b 13 (7,19) 51.2 35.6 32.1
Cystectomy 18 (7, 29) 57.2 20.3 20.3
aCDS: Cancer directed Surgery
bTURBT: Transurethral resection for bladder tumor.
Table 4: COX proportional multivariate analysis of factors associated with sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder
disease speciﬁc mortality.
Characteristics Group Hazard ratio 95% CI P value
Age Continuous 1.01 0.99–1.03 .45
Gender Male 1.00
Female 1.26 0.75–2.11 .39
Ethnicity White 1.00
Others 1.28 0.58–2.83 .55
SEER Stage
Localized 1.00
Regional 2.17 1.08–4.38 .03
Distant 8.86 4.03–19.51 <.0001
Unknown 1.72 0.64–4.62 .28
Married Yes 1.00
No 1.30 0.77–2.20 .33
Diagnose year
1973–1984 1.00
1985–1994 0.80 0.32–2.05 .65
1995–2004 1.15 0.47–2.82 .76
Cystectomy No 1.00
Yes 0.80 0.43–1.50 .49
Radiation No 1.00
Yes 1.15 0.64–2.09 .64
Combination∗ No 1.00
Yes 0.38 0.08–1.85 .23
HR=Hazard ratio; CI =Conﬁdence interval
∗Combination =combination therapy of cystectomy and radiation.
Most patients with carcinosarcoma of the urinary blad-
der in this study had high-histological grade and advanced
stage disease at the time of presentation: 148 of 204 (72.5%)
patients with known stage were classiﬁed as having regional
or distant stage; 125 of 127 (98.4%) patients with known
histology grade, had poorly or undiﬀerentiated histology
(Table 2). These ﬁndings were consistent with prior reports
that carcinosarcoma of the bladder is a highly aggressive
subtype of bladder cancer [2–10].
Approximately, 40% of the bladder carcinosarcoma
patients in this population were aﬀected by multiple primary
tumors. The previously underrecognized high incidence of
multiple primaries in patients with carcinosarcoma of the
urinary bladder suggests a common underlying mechanism
or pathway of carcinogenesis. Although the potential non-
random association and causal relationship between carci-
nosarcoma and other neoplasms remains unknown, ﬁeld
cancerization, cancer stem cell, or patient screening eﬀect
may account for the relatively frequent association of mul-
tiple primaries in patients with urogenital tumors [21–23].
Owing to the rareness of carcinosarcoma, and in the
absence of randomized controlled trials, there is no standardSarcoma 5
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Figure 1: (a)Cancer-speciﬁc survival rate of patients with car-
cinosarcoma of the bladder. (b) Cancer-speciﬁc survival rate
according to SEER stage. (c) Cancer-speciﬁc survival rate according
to status of cystectomy (TURBT: transurethral resection for bladder
tumor).
treatmentforthisdisease.Incontrasttonon-muscle-invasive
transitional cell carcinoma of the bladder, non muscle-
invasive carcinosarcoma of the urinary bladder usually
involves the lamina propria. In addition to the carcinoma-
tous degeneration of the mucosa, sarcomatous degeneration
of the underlying submucosal stroma is also present [24].
TURBT (transurethral resection for bladder tumor) or par-
tialcystectomy,carriestheriskofincompletetumorremoval.
Therefore, radical cystectomy appears to be the treatment of
choice for both superﬁcial and deeply invasive disease [25].
For muscle invasive disease, some authors advocate radical
treatment (i.e., cystectomy) whenever possible. Even though,
local recurrence and/or metastasis rates were very high after
radical surgery [24].
Consistent with single institution studies, the cancer
speciﬁc survival of this cohort of carcinosarcoma of the
urinary bladder was poor. In our study, the 1-, 5- and 10-
year survival rate of carcinosarcoma of the urinary bladder
were 53.9%, 28.4%, and 25.8% (Figure 1(a)), which is much
lower than the 5-year overall survival rate of bladder cancer
as whole [25]. In a multivariate survival analyses by Cox
proportional hazard modeling, tumor stage was the only
factorindependentlyassociatedwithcancer-speciﬁcsurvival.
Similarly, a previous report showed a mortality rate of 80%
at a mean followup of 14 months with pathologic stage
being the best single predictive factor of survival [9]. Tumor
stage also has been shown to be a strong predictor for
survival in patients with other subtypes of bladder cancer
such as urothelial carcinoma, squamous cell carcinoma,
adenocarcinoma, and small cell carcinoma [24, 26]. The
ﬁndings of this study, along with others [9], underscore the
importance of early detection and diagnosis in this disease.
The prognosis of this tumor remains poor, even in
patients with resectable disease. The overall 5-year cancer-
speciﬁc survival rate after cystectomy in our study popula-
tion was only 20.3%, suggesting a high risk of early dissemi-
nation.Recently,cystoprostatectomywithlymphadenectomy
plus various combinations of neoadjuvant or adjuvant
chemotherapy and/or radiotherapy has been advocated by
some authors [24, 26–29]. However, the outcomes have
been variable and inconsistent. While some authors reported
promising results with ovarian or sarcoma-type chemother-
apy regimens [30], others reported a poor outcomes regard-
less of the type of treatment [9]. Although the combination
of gemcitabine and cisplatin has been an eﬀective and
well-tolerated chemotherapy regimen for the treatment of
advanced urothelial carcinoma [31], there are only a
few case reports regarding its use in carcinosarcoma of the
urinary bladder [29, 32]. Multi-institution clinical trials are
needed to establish a better therapeutic protocol for this rare
but aggressive cancer.
Strengths of this study include the population-based
design with a large sample size and the inclusion of a wide
range of age and racial groups in the analysis. Large sample
size is of particular importance for analysis of rare tumors
such as carcinosarcoma of the urinary bladder, where it is
nearly impossible for a single institution to collect enough
cases to make meaningful predictions regarding important
prognostic factors and treatment recommendations.6 Sarcoma
Limitationsofthestudyincludeofthelackcentralreview
of pathology reports. In addition, information regarding
receipt of chemotherapy or patients’ comorbidities is not
available in SEER database, all of which may inﬂuence sur-
vival in cancer patients. However, the use of speciﬁc survival
rather than overall survival in our study has modiﬁed the
limitation to some degree. Finally, sample size in our study
may still not be enough to fully describe the factors that
aﬀect the incidence, treatment choice, and survival of this
rare tumor.
5. Conclusion
In summary, carcinosarcoma of the urinary bladder is a
highly malignant neoplasm, occurring predominantly in
elder males with an advanced stage at presentation and was
rapidly lethal. A better understanding of the natural history
of the disease and prognostic factors as provided herein
are necessary to allow physicians and patients to accurately
assess the risks and potential beneﬁts of treatment. Future
advances in the molecular biology of this disease may lead to
development of novel treatment strategies for this relatively
rare but complex disease.
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